ORIC Pharmaceuticals, Inc.
ORIC · Nasdaq · USD · Market cap $928M · 104 employees
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States.
Not enough data to screen yetPrice as of 20 Nov 2026Daily close, not a live quote
Screened 2026-11-20 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price7.36 USD at the 20 Nov 2026 close
- Fair valueUnder review: our model's value is 2.94x the price, above our 2.00x limit.
- Our regime readDistribution, as of 15 Nov 2026
- Ethical screenNot yet scored
- OptionsOpen interest leans to puts (put/call 34.60)
- Last reviewed20 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: range not available (screen dated 2026-11-20).
- Trend Distribution
- Insiders insiders sold, $86,524, latest filing 2026-10-01
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 34.60, read 2026-11-20
- Ethical screen not yet scored
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its distribution label.
ORIC Pharmaceuticals, Inc. holds its Distribution at $7.36. The statistical read favours the buyers, held for 17 days.
| Phase | Distribution · caution |
| Quantitative state | The statistical read favours the buyers, held for 17 days |
| Price at the screen | $7.36 |
| Valuation | N/A trailing · -5.31 forward price to earnings |
| Values screen | Not scored · score 70.0 |
| Beta | 0.98 |
Five Screens: ORIC's Results
This security has not been fully scored against the values screen yet.
| Test | Figure | Limit | Status |
|---|---|---|---|
| Business activity | Permissible | Permissible core business | Pass |
| Debt load | 0.81% | Below 33% | Pass |
| Interest-bearing cash | 27.09% | Below 33% | Pass |
| Receivables | 11.17% | Below 49% | Pass |
Definitions, sources and threshold rules: ticker values-screen methodology.
The Ethical ReadThe Read, in Plain English
ORIC Pharmaceuticals, clears the business-activity screen and the figures we can measure look clean, but its income-purity figure is still pending, so the verdict is not final yet.
Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.
What the Numbers Say It Is WorthThe Fair Value Range
Fair value under review. Our model's value is 2.94x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.
The Street's RangeStreet: 14 covering, consensus Strong Buy. Average target +219%.
| Forward P/E | -5.3x |
| EPS, trailing | -1.32 |
| EPS, forward | -1.69 |
| Profit margin | 0.0%currently unprofitable |
| Return on equity | -39.8%not currently earning a positive return on equity |
| FCF yield | -7.42% |
| Debt to equity | 1.57a meaningful debt load worth watching |
| Current ratio | 13.19comfortably covers its short-term bills |
| Beta | 0.98steadier than the market |
| Short interest, float | 0.16% |
| 52-week range | 7.23 - 14.68 |
| Market cap | $928M |
| Employees | 104 |
ORIC-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.
Metric definitions and interpretation rules: ticker-page methodology.
Every Entry, As Written
Earnings landed in this window. Ethical screening: not fully scored yet.
Written on its date, before the outcome; never pruned.
- Oric Pharmaceuticals’ Enozertinib Shows 88% Response Rate in EGFR Lung Cancer Study Yahoo Finance · 29d ago
- ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 Trial Yahoo Finance · 29d ago
- ORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress 2026 Yahoo Finance · 29d ago
- ORIC Stock In Focus As New Lung Cancer Trial Data Heads To ESMO 2026 Yahoo Finance · 21 Oct 2026
- ORIC® Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026 Yahoo Finance · 19 Oct 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-01 | Heyman Richard A. | Dir | S - Sale+OE | 6,700 | $86,524 |
| 2026-09-28 | Piscitelli Dominic | CFO | S - Sale+OE | 13,400 | $181,258 |
| 2026-09-24 | Piscitelli Dominic | CFO | S - Sale+OE | 600 | $8,103 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $8.99 | -15.0% | · | $850 | -15.0% |
| 2 months | $10.15 | -24.7% | · | $753 | -24.7% |
| 3 months | $11.76 | -35.0% | · | $650 | -35.0% |
| 6 months | $9.69 | -21.1% | · | $789 | -21.1% |
| 1 year | $9.75 | -21.6% | · | $784 | -21.6% |
| 2 years | $8.60 | -11.1% | · | $889 | -11.1% |
| 3 years | $5.15 | +48.5% | · | $1,485 | +48.5% |
| 5 years | $19.52 | -60.8% | · | $392 | -60.8% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever ORIC does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.